CSL (OTCMKTS:CSLLY) Shares Gap Up – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped up before the market opened on Tuesday . The stock had previously closed at $23.95, but opened at $28.2350. CSL shares last traded at $27.99, with a volume of 37,269 shares.

Wall Street Analyst Weigh In

CSLLY has been the topic of a number of research reports. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Finally, Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, CSL has an average rating of “Hold”.

CSL Stock Up 17.0%

The stock has a 50 day simple moving average of $21.12 and a 200 day simple moving average of $27.51. The company has a quick ratio of 1.15, a current ratio of 2.57 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.